Immunomodulatory activities and biomedical applications of melittin and its recent advances
Archiv der Pharmazie · 2024-04 · 357 (4)
DOI: 10.1002/ardp.202300569 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 22.01.2024. Verfasst von Zohreh Jafari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Bee Venoms, Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 257 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Melittin (MLT), a peptide containing 26 amino acids, is a key constituent of bee venom. It comprises ∼40%–60% of the venom's dry weight and is the main pricing index for bee venom, being the causative factor of pain. The unique properties of MLT extracted from bee venom have made it a very valuable active ingredient in the pharmaceutical industry as this cationic and amphipathic peptide has propitious effects on human health in diverse biological processes. It has the ability to strongly impact the membranes of cells and display hemolytic activity with anticancer characteristics. However, the clinical application of MLT has been limited by its severe hemolytic activity, which poses a challenge for therapeutic use. By employing more efficient mechanisms, such as modifying the MLT sequence, genetic engineering, and nano‐delivery systems, it is anticipated that the limitations posed by MLT can be overcome, thereby enabling its wider application in therapeutic contexts. This review has outlined recent advancements in MLT's nano‐delivery systems and genetically engineered cells expressing MLT and provided an overview of where the MLTMLT's platforms are and where they will go in the future with the challenges ahead. The focus is on exploring how these approaches can overcome the limitations associated with MLT's hemolytic activity and improve its selectivity and efficacy in targeting cancer cells. These advancements hold promise for the creation of innovative and enhanced therapeutic approaches based on MLT for the treatment of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Institute of Polymers, Composites and Biomaterials, National Research Council of Italy (IPCB-CNR), Naples, Italy.
- Department of Chemical, Materials and Production Engineering, University of Naples Federico II, Naples, Italy.
- Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
- Department of Biotechnology, Faculty of Pharmacy, Alborz University of Medical Sciences, Karaj, Iran.
- Medical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Förderung
- None
Zitieren
APA
Jafari, Z., Sadeghi, S., Dehaghi, M. M., Bigham, A., Honarmand, S., Tavasoli, A., Hoseini, M. H. M., & Varma, R. S. (2024). Immunomodulatory activities and biomedical applications of melittin and its recent advances. Archiv der Pharmazie, 357(4). https://doi.org/10.1002/ardp.202300569
Vancouver
Jafari Z, Sadeghi S, Dehaghi MM, Bigham A, Honarmand S, Tavasoli A, et al. Immunomodulatory activities and biomedical applications of melittin and its recent advances. Archiv der Pharmazie. 2024;357(4). doi:10.1002/ardp.202300569
BibTeX
@article{Jafari2024,
author = {Jafari, Zohreh and Sadeghi, Sahar and Dehaghi, Mahsa Mirzarazi and Bigham, Ashkan and Honarmand, Shokouh and Tavasoli, Afsaneh and Hoseini, Mostafa Haji Molla and Varma, Rajender S},
title = {Immunomodulatory activities and biomedical applications of melittin and its recent advances},
journal = {Archiv der Pharmazie},
year = {2024},
volume = {357},
number = {4},
doi = {10.1002/ardp.202300569}
}
EUVIMED